Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast (ARKK:BATS)

Ark Invest, led by Cathie Wood, increased stakes in AI and biotech, buying $25.9M of CoreWeave, $24.4M of Meta, and $17.6M of Recursion. It also acquired $16.3M of Cerebras.

Original reporting
Published Oct 19, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CRWV
Bullish
medium confidence
Mentioned
$CRWV · $META · $RXRX · $PSNL
Relevance
4/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CRWVBullishLow
01

Why it matters

Fund activity can influence short-term price movements but does not constitute a material corporate event.

02

Market read

Ark's purchases provide modest buying pressure on the listed stocks mentioned.

03

What to watch

Potential dilution from future fund purchases or broader market volatility.

Relevance 4/10Novelty 3/10Timing: today

Background

Ark Invest's weekly portfolio update shows new allocations to AI infrastructure and biotech.

Company-level read

Ticker impact

$CRWVBullishMedium confidence
Context

Ark Invest bought $25.9M of CoreWeave shares, increasing its stake.

Expected impact

likely upward pressure as the market prices in the new ownership stake

Evidence & confidence

Fund buying signals confidence and can lift price in the short term.

$METABullishMedium confidence
Context

Ark Invest added $24.4M of Meta Platforms shares to its portfolio.

Expected impact

likely modest upside from fund buying

Evidence & confidence

Large-cap stocks are less sensitive, but institutional buying can provide a boost.

$RXRXBullishMedium confidence
Context

Ark Invest purchased $17.6M of Recursion Pharmaceuticals shares.

Expected impact

likely upward pressure as investors note the endorsement

Evidence & confidence

Biotech stocks often react to fund inflows, especially from a high-profile manager.

Market effects

Highlights continued institutional interest in AI and biotech sectors.

U.S. market focus, no specific regional effect.

Reinforces global narrative of AI investment.

Counterpoint

Fund buying may be already priced in; limited upside.

Key entities

  • Ark Invest

    Active manager increasing exposure to AI and biotech.

Related articles

$NVDAHighAI 9/10

Nvidia earnings beat lifts Bitcoin mining stocks

Nvidia (NVDA) reported Q3 2026 earnings, beating estimates with $2.68 EPS and $115.8B revenue. Data center revenue rose 110% YoY. Q4 outlook is $127.4B-$132.6B, above analyst estimates. Bitcoin mining stocks like MARA, HUT, RIOT, IREN, and CRWV rose, as some pivot to AI due to rising mining costs and Bitcoin's price drop.

$SNDKLow

Leopold Aschenbrenner’s AI Fund Cut Its Reported Holdings 92% in One Quarter

Leopold Aschenbrenner's AI fund, Situational Awareness, reduced its reported holdings by 92% to $1.58 billion in Q3, according to 13F filings. The fund sold stakes in SanDisk, Micron, Bloom Energy, Nebius, and CoreWeave, shifting into options. New top holding is SharonAI at $441 million. Micron and SanDisk reported revenue growth, while Bloom raised guidance. CoreWeave and Nebius faced financial challenges.

$NVDAMed

Nvidia’s Interim CEO: Old Hopper GPUs Recontracted at “Up to Twice Their Original Price.” Good News for CoreWeave

Nvidia's interim CEO reported that older Hopper GPUs were recontracted at up to twice their original price, benefiting companies like CoreWeave, Nebius, and IREN. CoreWeave, despite a $709 million Q3 loss, saw a 2% rise in shares. The news supports the longevity of GPU earnings, addressing depreciation concerns. Analysts expect CoreWeave's revenue to grow significantly by 2028.